The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Pseudomonas aeruginosa is a bacterial pathogen associated with a wide range of infections and utilizes several strategies to establish and maintain infection including biofilm production, multidrug resistance, and antibiotic tolerance. Multidrug resistance in P. aeruginosa, as well as in all other bacterial pathogens, is a growing concern. Aminoglycoside resistance, in particular, is a major concern in P. aeruginosa infections and must be better understood in order to maintain effective clinical treatment. In this review, the various antibiotic resistance and tolerance mechanisms of Pseudomonas are explored including: classic mutation driven resistance, adaptive resistance, persister cells, small colony variants, phoenix colonies, and biofilms. It is important to further characterize each of these phenotypes and continue to evaluate antibiotic surviving isolates for novel driving mechanisms, so that we are better prepared to combat the rising number of recurrent and recalcitrant infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“P. aeruginosa growth in biofilms increases its tolerance to antimicrobials (reviewed in ref. 73) (Fig. 3b)”
From Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility (2025) · cites this paper as [73]
In the citing paper
“These bacterial communities demonstrate high resistance to most antibacterial agents as well as to host defenses [9,15,16,17].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Persister cells, dormancy and infectious disease
Lewis, K. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1557 · Cited by 2,052 · cited 1×
“Persister cells develop at a low rate (~1% of the population [65]), however, it is a major concern due to the possibility of them leading to recurrent infections [8], although this has yet to be confirmed in a clinical study.”
BackgroundLewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation
Drenkard, E., & Ausubel, F. M. (2002) · Nature · doi:10.1038/416740a · Cited by 997
Mechanisms and clinical relevance of bacterial heteroresistance
Andersson, D. I., Nicoloff, H., & Hjort, K. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0218-1 · Cited by 513
Antimicrobial heteroresistance: An emerging field in need of clarity
El-Halfawy, O. M., & Valvano, M. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-14 · Cited by 489 · cited 1×
“detected [40,41] and it is possible that this could lead to treatment failure [41,42].”
BackgroundTseng, B. S., Zhang, W., Harrison, J. J., Quach, T. P., Song, J. L., Penterman, J., Singh, P. K., Chopp, D. L., Packman, A. I., & Parsek, M. R. (2013) · Environmental Microbiology · doi:10.1111/1462-2920.12155 · Cited by 466 · cited 4×
“The EPS matrix is comprised of polysaccharides, proteins, eDNA, and lipids and provides a scaffolding structure for the bacteria within the biofilm [89,90].”
BackgroundInfluentialStewart, P. S., Zhang, T., Xu, R., Pitts, B., Walters, M. C., Roe, F., Kikhney, J., & Moter, A. (2016) · npj Biofilms and Microbiomes · doi:10.1038/npjbiofilms.2016.12 · Cited by 157 · cited 1×
“Both the slow growth and persister cell phenotypes exhibit an increased tolerance to antibiotics [55,102].”
Background
Research works printed but not linked: 101
- Malhotra, 2019, Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface, Clin Microbiol Rev, 32, 10.1128/CMR.00138-18 · DOI · Paper page
- Shah, 2016, Pseudomonas prosthetic joint infections: a review of 102 episodes, J Bone Jt Infect, 1, 25, 10.7150/jbji.15722 · doi:10.7150/jbji.15722
- Serra, 2015, Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus, Expert Rev Anti Infect Ther, 13, 605, 10.1586/14787210.2015.1023291 · DOI · Paper page
- Ciofu, 2019, Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics, Front Microbiol, 10, 913, 10.3389/fmicb.2019.00913 · DOI · Paper page
- Lewis, 2008, Multidrug tolerance of biofilms and persister cells, Curr Top Microbiol Immunol, 322, 107
- Zavascki, 2010, Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy, Expert Rev Anti Infect Ther, 8, 71, 10.1586/eri.09.108 · DOI · Paper page
- Hall-Stoodley, 2005, Biofilm formation and dispersal and the transmission of human pathogens, Trends Microbiol, 13, 7, 10.1016/j.tim.2004.11.004 · DOI · Paper page
- Cross, 1983, Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance, Arch Intern Med, 143, 2075, 10.1001/archinte.1983.00350110053015 · doi:10.1001/archinte.1983.00350110053015
- Blahova, 2001, Sudden increase in Pseudomonas aeruginosa nosocomial strains with broad host range transfer of antibiotic resistance, J Chemother, 13, 607, 10.1179/joc.2001.13.6.607 · doi:10.1179/joc.2001.13.6.607
- Zignol, 2006, Global incidence of multidrug-resistant tuberculosis, J Infect Dis, 194, 479, 10.1086/505877 · DOI · Paper page
- Keen, 2010, Prevalence of multidrug-resistant organisms recovered at a military burn center, Burns, 36, 819, 10.1016/j.burns.2009.10.013 · DOI · Paper page
- Tam, 2010, Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 54, 1160, 10.1128/AAC.01446-09 · DOI
- Oliver, 2000, High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection, Science, 288, 1251, 10.1126/science.288.5469.1251 · DOI · Paper page
- Gilleland, 1989, Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa, J Med Microbiol, 29, 41, 10.1099/00222615-29-1-41 · doi:10.1099/00222615-29-1-41
- Poole, 2005, Aminoglycoside resistance in Pseudomonas aeruginosa, Antimicrob Agents Chemother, 49, 479, 10.1128/AAC.49.2.479-487.2005 · DOI · Paper page
- Prickett, 2017, Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene, Thorax, 72, 40, 10.1136/thoraxjnl-2015-208027 · DOI
- Levin-Reisman, 2017, Antibiotic tolerance facilitates the evolution of resistance, Science, 355, 826, 10.1126/science.aaj2191 · DOI · Paper page
- Jalal, 2000, Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients, Antimicrob Agents Chemother, 44, 710, 10.1128/AAC.44.3.710-712.2000 · DOI · Paper page
- Bryan, 1976, Gentamicin resistance in clinical-isolates of Pseudomonas aeruginosa associated with diminished gentamicin accumulation and no detectable enzymatic modification, J Antibiot (Tokyo), 29, 743, 10.7164/antibiotics.29.743 · doi:10.7164/antibiotics.29.743
- Doi, 1968, Inactivation of kanamycin, neomycin, and streptomycin by enzymes obtained in cells of Pseudomonas aeruginoa, Appl Microbiol, 16, 1276, 10.1128/am.16.9.1276-1281.1968 · doi:10.1128/am.16.9.1276-1281.1968
- Brzezinska, 1972, Gentamicin resistance in strains of Pseudomonas aeruginosa mediated by enzymatic N-acetylation of the deoxystreptamine moiety, Biochemistry, 11, 761, 10.1021/bi00755a013 · doi:10.1021/bi00755a013
- Kobayashi, 1971, Inactivation of dihydrostreptomycin by Pseudomonas aeruginosa, Jpn J Microbiol, 15, 381, 10.1111/j.1348-0421.1971.tb00596.x · doi:10.1111/j.1348-0421.1971.tb00596.x
- Seupt, 2020, Expression of the MexXY aminoglycoside efflux pump and presence of an aminoglycoside-modifying enzyme in clinical Pseudomonas aeruginosa isolates are highly correlated, Antimicrob Agents Chemother, 65, 10.1128/AAC.01166-20 · doi:10.1128/aac.01166-20
- Kashfi Mh, 2017, The prevalence of aminoglycoside-modifying enzyme genes among Pseudomonas aeruginosa strains isolated from burn patients, Arch Clin Infect Dis, 12
- Rodriguez Esparragon, 2000, Aminoglycoside resistance mechanisms in clinical isolates of Pseudomonas aeruginosa from the Canary Islands, Zentralbl Bakteriol, 289, 817, 10.1016/S0934-8840(00)80008-0 · doi:10.1016/s0934-8840(00)80008-0
- Thirumalmuthu, 2019, Mechanisms of fluoroquinolone and aminoglycoside resistance in keratitis-associated Pseudomonas aeruginosa, Microb Drug Resist, 25, 813, 10.1089/mdr.2018.0218 · DOI
- Pan, 2017, In vivo host environment alters Pseudomonas aeruginosa susceptibility to aminoglycoside antibiotics, Front Cell Infect Microbiol, 7, 83, 10.3389/fcimb.2017.00083 · doi:10.3389/fcimb.2017.00083
- Terzi, 2014, The effects of active efflux pumps on antibiotic resistance in Pseudomonas aeruginosa, World J Microbiol Biotechnol, 30, 2681, 10.1007/s11274-014-1692-2 · DOI
- Rampioni, 2017, Effect of efflux pump inhibition on Pseudomonas aeruginosa transcriptome and virulence, Sci Rep, 7, 11392, 10.1038/s41598-017-11892-9 · DOI
- Horna, 2018, Interplay between MexAB-OprM and MexEF-OprN in clinical isolates of Pseudomonas aeruginosa, Sci Rep, 8, 16463, 10.1038/s41598-018-34694-z · DOI
- Laborda, 2019, Novel inducers of the expression of multidrug efflux pumps that trigger Pseudomonas aeruginosa transient antibiotic resistance, Antimicrob Agents Chemother, 63, 10.1128/AAC.01095-19 · DOI
- Halfon, 2019, Structure of Pseudomonas aeruginosa ribosomes from an aminoglycoside-resistant clinical isolate, Proc Natl Acad Sci U S A, 116, 22275, 10.1073/pnas.1909831116 · DOI
- Sanz-Garcia, 2019, Analysis of the Pseudomonas aeruginosa aminoglycoside differential resistomes allows defining genes simultaneously involved in intrinsic antibiotic resistance and virulence, Antimicrob Agents Chemother, 63, 10.1128/AAC.00185-19 · doi:10.1128/aac.00185-19
- Freschi, 2019, The Pseudomonas aeruginosa pan-genome provides new insights on its population structure, horizontal gene transfer, and pathogenicity, Genome Biol Evol, 11, 109, 10.1093/gbe/evy259 · DOI · Paper page
- Hermes, 2013, Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa, J Med Microbiol, 62, 1184, 10.1099/jmm.0.059220-0 · DOI
- He, 2018, Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections, Int J Antimicrob Agents, 51, 413, 10.1016/j.ijantimicag.2017.10.014 · DOI
- Xu, 2020, Mechanisms of heteroresistance and resistance to imipenem in Pseudomonas aeruginosa, Infect Drug Resist, 13, 1419, 10.2147/IDR.S249475 · DOI · Paper page
- Band, 2019, Heteroresistance: a cause of unexplained antibiotic treatment failure?, PLoS Pathog, 15, 10.1371/journal.ppat.1007726 · DOI · Paper page
- Band, 2018, Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection, mBio, 9, 10.1128/mBio.02448-17 · DOI
- Anderson, 2018, Aminoglycoside heteroresistance in acinetobacter baumannii AB5075, mSphere, 3, 10.1128/mSphere.00271-18 · DOI
- Nicoloff, 2019, The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification, Nat Microbiol, 4, 504, 10.1038/s41564-018-0342-0 · DOI · Paper page
- Band, 2019, Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection, Nat Microbiol, 4, 1627, 10.1038/s41564-019-0480-z · DOI · Paper page
- Barclay, 1996, Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis, J Antimicrob Chemother, 37, 1155, 10.1093/jac/37.6.1155 · DOI
- Alford, 2021, NtrBC selectively regulates host-pathogen interactions, virulence, and ciprofloxacin susceptibility of Pseudomonas aeruginosa, Front Cell Infect Microbiol, 11, 694789, 10.3389/fcimb.2021.694789 · DOI
- Skiada, 2011, Adaptive resistance to cationic compounds in Pseudomonas aeruginosa, Int J Antimicrob Agents, 37, 187, 10.1016/j.ijantimicag.2010.11.019 · DOI
- Coleman, 2020, Multidrug adaptive resistance of Pseudomonas aeruginosa swarming cells, Antimicrob Agents Chemother, 64, 10.1128/AAC.01999-19 · doi:10.1128/aac.01999-19
- Grassi, 2017, Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents, Front Microbiol, 8, 1917, 10.3389/fmicb.2017.01917 · DOI
- Renbarger, 2017, Slow and steady wins the race: an examination of bacterial persistence, AIMS Microbiol, 3, 171, 10.3934/microbiol.2017.2.171 · DOI
- Hobby, 1942, Observations on the mechanism of action of penicillin, Proc Soc Exp Biol Med, 50, 281, 10.3181/00379727-50-13773 · DOI · Paper page
- Bigger, 1944, Treatment of staphylococcal infections with penicillin by intermittent sterilisation, Lancet, 244, 497, 10.1016/S0140-6736(00)74210-3 · DOI · Paper page
- Soares, 2019, Understanding ciprofloxacin failure in Pseudomonas aeruginosa biofilm: persister cells survive matrix disruption, Front Microbiol, 10, 2603, 10.3389/fmicb.2019.02603 · DOI
- Zhou, 2021, Identification of a toxin-antitoxin system that contributes to persister formation by reducing NAD in Pseudomonas aeruginosa, Microorganisms, 9, 10.3390/microorganisms9040753 · DOI
- Andersen, 2017, Diversity, prevalence, and longitudinal occurrence of type II toxin-antitoxin systems of Pseudomonas aeruginosa infecting cystic fibrosis lungs, Front Microbiol, 8, 1180, 10.3389/fmicb.2017.01180 · doi:10.3389/fmicb.2017.01180
- Kim, 2010, Toxins Hha and CspD and small RNA regulator Hfq are involved in persister cell formation through MqsR in Escherichia coli, Biochem Biophys Res Commun, 391, 209, 10.1016/j.bbrc.2009.11.033 · DOI · Paper page
- Dorr, 2010, Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli, PLoS Biol, 8, 10.1371/journal.pbio.1000317 · DOI · Paper page
- Brown, 2009, Three dimensional structure of the MqsR:MqsA complex: a novel TA pair comprised of a toxin homologous to RelE and an antitoxin with unique properties, PLoS Pathog, 5, 10.1371/journal.ppat.1000706 · DOI · Paper page
- Gonzalez Barrios, 2006, Autoinducer 2 controls biofilm formation in Escherichia coli through a novel motility quorum-sensing regulator (MqsR, B3022), J Bacteriol, 188, 305, 10.1128/JB.188.1.305-316.2006 · DOI · Paper page
- Ren, 2004, Gene expression in Escherichia coli biofilms, Appl Microbiol Biotechnol, 64, 515, 10.1007/s00253-003-1517-y · DOI · Paper page
- Hong, 2012, Bacterial persistence increases as environmental fitness decreases, Microb Biotechnol, 5, 509, 10.1111/j.1751-7915.2011.00327.x · DOI · Paper page
- Mulcahy, 2010, Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis, J Bacteriol, 192, 6191, 10.1128/JB.01651-09 · DOI · Paper page
- Zierdt, 1964, Dissociation in Pseudomonas aeruginosa, J Bacteriol, 87, 1003, 10.1128/jb.87.5.1003-1010.1964 · DOI
- Haussler, 1999, Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis, Clin Infect Dis, 29, 621, 10.1086/598644 · DOI · Paper page
- Melter Or, 2010, Small colony variants of staphylococcus aureus - review, Folia Microbiol, 55, 10.1007/s12223-010-0089-3 · DOI
- Boles, 2004, Self-generated diversity produces "insurance effects" in biofilm communities, Proc Natl Acad Sci U S A, 101, 16630, 10.1073/pnas.0407460101 · DOI · Paper page
- Pestrak Mjc, 2018, Pseudomonas aeruginosa rugose small-colony variants evade host clearance, are hyper-inflammatory, and persist in multiple host environments, PLoS Pathog, 14
- D'Argenio, 2002, Autolysis and autoaggregation in Pseudomonas aeruginosa colony morphology mutants, J Bacteriol, 184, 6481, 10.1128/JB.184.23.6481-6489.2002 · DOI · Paper page
- Ross, 1987, Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid, Nature, 325, 279, 10.1038/325279a0 · DOI · Paper page
- Boyd, 2012, Second messenger regulation of biofilm formation: breakthroughs in understanding c-di-GMP effector systems, Annu Rev Cell Dev Biol, 28, 439, 10.1146/annurev-cellbio-101011-155705 · DOI · Paper page
- Hickman, 2008, Identification of FleQ from Pseudomonas aeruginosa as a c-di-GMP-responsive transcription factor, Mol Microbiol, 69, 376, 10.1111/j.1365-2958.2008.06281.x · DOI · Paper page
- Baraquet, 2012, The FleQ protein from Pseudomonas aeruginosa functions as both a repressor and an activator to control gene expression from the pel operon promoter in response to c-di-GMP, Nucleic Acids Res, 40, 7207, 10.1093/nar/gks384 · DOI · Paper page
- Malone, 2010, YfiBNR mediates cyclic di-GMP dependent small colony variant formation and persistence in Pseudomonas aeruginosa, PLoS Pathog, 6, 10.1371/journal.ppat.1000804 · DOI · Paper page
- Starkey, 2009, Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung, J Bacteriol, 191, 3492, 10.1128/JB.00119-09 · DOI · Paper page
- Blanka, 2015, Constitutive production of c-di-GMP is associated with mutations in a variant of Pseudomonas aeruginosa with altered membrane composition, Sci Signal, 8, ra36, 10.1126/scisignal.2005943 · DOI
- Kirisits, 2005, Characterization of colony morphology variants isolated from Pseudomonas aeruginosa biofilms, Appl Environ Microbiol, 71, 4809, 10.1128/AEM.71.8.4809-4821.2005 · DOI · Paper page
- Hickman, 2005, A chemosensory system that regulates biofilm formation through modulation of cyclic diguanylate levels, Proc Natl Acad Sci U S A, 102, 14422, 10.1073/pnas.0507170102 · DOI · Paper page
- Jennings Lks, 2015, Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix, Proc Natl Acad Sci U S A, 112
- Schiessl, 2019, Phenazine production promotes antibiotic tolerance and metabolic heterogeneity in Pseudomonas aeruginosa biofilms, Nat Commun, 10, 762, 10.1038/s41467-019-08733-w · DOI · Paper page
- Glasser Nrk, 2014, Phenazine redox cycling enhances anaerobic survival in Pseudomonas aeruginosa by facilitating generation of ATP and a proton-motive force, Mol Microbiol, 92
- McCurtain, 2019, Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation, J Med Microbiol, 68, 446, 10.1099/jmm.0.000928 · DOI
- Sindeldecker, 2020, Novel aminoglycoside-tolerant phoenix colony variants of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 64, 10.1128/AAC.00623-20 · DOI
- Satola, 2011, Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method, J Clin Microbiol, 49, 177, 10.1128/JCM.01128-10 · DOI
- Tolker-Nielsen, 2015, Biofilm development, Microbiol Spectr, 3, 10.1128/microbiolspec.MB-0001-2014 · DOI · Paper page
- Skariyachan, 2018, Recent perspectives on the molecular basis of biofilm formation by Pseudomonas aeruginosa and approaches for treatment and biofilm dispersal, Folia Microbiol, 63, 413, 10.1007/s12223-018-0585-4 · DOI
- Maurice, 2018, Pseudomonas aeruginosa biofilms: host response and clinical implications in lung infections, Am J Respir Cell Mol Biol, 58, 428, 10.1165/rcmb.2017-0321TR · DOI · Paper page
- Marmont, 2017, PelA and PelB proteins form a modification and secretion complex essential for Pel polysaccharide-dependent biofilm formation in Pseudomonas aeruginosa, J Biol Chem, 292, 19411, 10.1074/jbc.M117.812842 · DOI
- Jones, 2017, Psl produced by mucoid Pseudomonas aeruginosa contributes to the establishment of biofilms and immune evasion, mBio, 8, 10.1128/mBio.00864-17 · DOI
- Jenal, 2017, Cyclic di-GMP: second messenger extraordinaire, Nat Rev Microbiol, 15, 271, 10.1038/nrmicro.2016.190 · DOI · Paper page
- Song, 2018, Cyclic-di-GMP and oprF are involved in the response of Pseudomonas aeruginosa to substrate material stiffness during attachment on polydimethylsiloxane (PDMS), Front Microbiol, 9, 110, 10.3389/fmicb.2018.00110 · DOI
- Kahl, 2020, Light-Mediated decreases in cyclic di-GMP levels inhibit structure formation in Pseudomonas aeruginosa biofilms, J Bacteriol, 202, 10.1128/JB.00117-20 · DOI
- Mukherjee, 2017, The RhlR quorum-sensing receptor controls Pseudomonas aeruginosa pathogenesis and biofilm development independently of its canonical homoserine lactone autoinducer, PLoS Pathog, 13, 10.1371/journal.ppat.1006504 · DOI · Paper page
- Kostylev, 2019, Evolution of the Pseudomonas aeruginosa quorum-sensing hierarchy, Proc Natl Acad Sci U S A, 116, 7027, 10.1073/pnas.1819796116 · DOI · Paper page
- Walters, 2003, Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin, Antimicrob Agents Chemother, 47, 317, 10.1128/AAC.47.1.317-323.2003 · DOI · Paper page
- Bernier, 2013, Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin, PLoS Genet, 9, 10.1371/journal.pgen.1003144 · DOI · Paper page
- Nguyen, 2011, Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria, Science, 334, 982, 10.1126/science.1211037 · DOI · Paper page
- Nicholle, 2014, Catheter associated urinary tract infections, Antimicrob Resist Infect Contr, 25
- Xu Wh, 2015, The effect of infection control nurses on the occurrence of Pseudomonas aeruginosa healthcare-acquired infection and multidrug-resistant strains in critically ill children, PloS One, 10
- Mulcahy Lri, 2014, Pseudomonas aeruginosa biofilms in disease, Microb Ecol, 68
- Stewart, 2002, Mechanisms of antibiotic resistance in bacterial biofilms, Int J Med Microbiol, 292, 107, 10.1078/1438-4221-00196 · DOI · Paper page
- Pachori, 2019, Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review, Genes Dis, 6, 109, 10.1016/j.gendis.2019.04.001 · DOI · Paper page
- Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies, Biotechnol Adv, 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
- Hoiby, 2017, Diagnosis of biofilm infections in cystic fibrosis patients, APMIS, 125, 339, 10.1111/apm.12689 · DOI
Cited by
Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility
Letizia, M., Diggle, S. P., & Whiteley, M. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01193-8 · Cited by 231
Verdial, C., Serrano, I., Tavares, L., Gil, S., & Oliveira, M. (2023) · Biomedicines · doi:10.3390/biomedicines11041221 · Cited by 71
“Biofilms, the main form of bacterial growth, are ubiquitous complex structures irreversibly attached to surfaces, consisting of an interactive polymicrobial community embedded in a self-produced matrix of polymeric extracellular substances, composed by polysaccharides, proteins, and eDNA [3,33,129].”
BackgroundSerrano, I., Alhinho, B., Cunha, E., Tavares, L., Trindade, A., & Oliveira, M. (2023) · Life · doi:10.3390/life13020504 · Cited by 33
Metadata
- Authors
- Sindeldecker, D., & Stoodley, P.
- Venue
- Biofilm
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 3
- Pages
- 100056
- ISSN
- 2590-2075
- Cited by
- 77
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- NIH
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.1016/j.bioflm.2021.100056
- The paper
- Sindeldecker, D., & Stoodley, P. (2021). The many antibiotic resistance and tolerance strategies of Pseudomonas aeruginosa. Biofilm. https://doi.org/10.1016/j.bioflm.2021.100056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.